It is important to note that there is variability among human clinical data and our model only makes predictions for the average human
So when we say what works in 2026, we mean: The peptide has a plausible mechanism that matches the goal There is human evidence, or strong clinical track record, not just theory The risk profile is understood It fits into a plan that includes labs, lifestyle, and follow up The peptide categories that matter most for wellness in 2026 Instead of a random list, it helps to organize peptides by what they are actually used for
Available in 60- and 90-serving powder sizes
Statements Author contributions QZ: Writingoriginal draft, Writingreview and editing
Retatrutide as the Reference Triple Agonist Retatrutide is the first triple agonist peptide to reach Phase 2 and Phase 3 clinical trials, and remains the reference compound for the category
Because we control the entire production process, we can guarantee competitive wholesale pricing and rapid lead times